Ignite Creation Date:
2024-05-06 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04691011
Status:
RECRUITING
Last Update Posted:
2023-07-20
First Post:
2020-10-22
Brief Title:
New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis
Sponsor:
Assistance Publique Hopitaux De Marseille
Organization:
Assistance Publique Hopitaux De Marseille
Study Overview
Official Title:
New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis
Status:
RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IRM-SLA
Brief Summary:
Amyotrophic lateral sclerosis ALS is a disabling and rapidly progressive neurodegenerative disorder There is no treatment that significantly slows progression Our project aims to find new biomarkers in MRI at three levels cerebral medullary and muscular These markers could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and to quantify these lesions to measure the progression of the disease This study will use advanced Magnetic Resonance Imaging MRI techniques High field 3T and very high field 7T MRI Results from neurological and electrophysiological tests will be compared to the MRI Subjects will be recruited from ALS center of Marseille France MRI will be done on ALS patients at baseline at 3 month and at 6 month intervals
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None